Apixaban Better Than Rivaroxaban in Reducing Stroke and Bleeding Risks, Study Shows

 A study has shown that the use of apixaban for nonvalvular atrial fibrillation or NVAF seems better than rivaroxaban in reducing the risks of stroke and bleeding but is correlated with similar risks relative to dabigatran.

Photo: Various Medications | InStyleHealth


Researchers conducted multicenter matched cohort studies with secondary meta-analyses to evaluate the safety and effectiveness of dabigatran, rivaroxaban, and apixaban across nine administrative healthcare databases. Also, they included adults with NVAF initiating direct oral anticoagulants or DOACs and divided them into three groups to compare DOACs pairwise.

Primary endpoint was the pooled hazard ratio or pHR of ischemic stroke or systemic thromboembolism; secondary ones were pHRs of major bleeding and a composite of stroke, major bleeding, or all-cause mortality. Proportional hazard Cox regression models were used, and pooled estimates were obtained through random effect meta-analyses.

In total, there were 73,414 new users of dabigatran, 92,881 of rivaroxaban, and 61,284 of apixaban. For rivaroxaban vs dabigatran, the pHRs were 1.11 for ischemic stroke or systemic embolism, 1.26 for major bleeding, and 1.17 for the composite endpoint.

pHRs comparing apixaban to dabigatran were 0.91, and 1.17 for ischemic stroke or systemic embolism, major bleeding, and the composite endpoint, correspondingly. For apixaban vs rivaroxaban, the corresponding pHRs were as follows: 0.85, 0.61, and 0.83.

 

Source: Br J Clin Pharmacol 2021;87:2589-2601

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post